About SLATE Therapeutics
SLATE Therapeutics is dedicated to revolutionizing the
treatment of chronic rhinosinusitis (CRS) with SilexGel, a novel
sol-gel hydrogel technology.
Our mission is to improve patients' quality of life through
innovative and effective treatments.
Our Unique Technology
SilexGel is a cutting-edge platform technology designed for the systemic and localized delivery of therapeutics. Unlike drug-eluting implants that tend to migrate and cause side effects, or nasal sprays that offer short-term relief, SilexGel provides long-lasting effects with minimal side effects.
SilexGel features & benefits
Sol-gel administration amenable to systemic & localized therapeutics
Rapid sol-gel hydrogel containing therapeutic particles (small molecule, macromolecule, cells), which adheres to mucosal surfaces long after full gel absorption.
Sol-Gel formulation conforms to body cavities. Agnostic to sinus or nasal anatomy and is designed to provide sustained therapy at the point of disruption.
IP
Our proprietary sol-gel hydrogel technology boasts a robust IP portfolio with comprehensive freedom to operate, underpinned by unique, newly discovered mechanisms. This innovative approach grants us a significant competitive edge in the treatment of sinusitis, offering unparalleled therapeutic efficacy and adhesion to mucosal surfaces. Our advancements not only set us apart in the sol-gel hydrogel market but also pave the way for superior, long-lasting treatment solutions for sinusitis, positioning us as leaders in this transformative field.
Clinical Need - CRS
Affects of the population worldwide
10%-
%
Annual medication costs
$1.5K-$
K
per patient*
Direct costs
$10B-$
B
per year in the USA**
Indirect costs
$
B
per year in the USA*
*Smith KA, Orlandi RR, Rudmik L. Cost of adult chronic rhinosinusitis: A systematic review. Laryngoscope. 2015 Jul;125(7):1547-56. ** Rudmik L. Economics of Chronic Rhinosinusitis. Curr Allergy Asthma Rep. 2017 Apr;17(4):20
Uncompromising Treatment
SilexGel VS Current Solutions
Drug eluting
implants
implants
Nasal sprays &
Systemic drugs
Systemic drugs
Dilation
SilexGel
Efficiency
Long Lasting
Short Term
Short Term
Long Lasting
Side effects
Frequent
Frequent
Minimal
Minimal
Market Opportunity
-
Sinus steroid delivery (Primary Application) Local, sustained steroid delivery Treatment of sinus tissue inflammation Replace sinus stents ($2B dilatation mkt)
-
Long-Term Acting Oral Drugs ($50B+ mkt) (Future Application) A long-acting, orally available platform can address a wide range of indications, including cardiovascular diseases, chronic conditions, psychiatric disorders, and obesity drugs (improved bioavailability).
-
Direct-to-brain delivery (Initial Application) Neurological diseases or other CNS ($17B market) No need to traverse BBB, direct route FDA approval for 1st depression nasal spray (2019) Targets: neurodegenerative, migraine, psychedelics, etc.
Sinus steroid delivery
(Primary Application)
Local, sustained steroid delivery
Treatment of sinus tissue inflammation
Replace sinus stents ($2B dilatation mkt)
Long-Term Acting Oral Drugs ($50B+ mkt)
(Future Application)
A long-acting, orally available platform can address a wide range of indications, including cardiovascular diseases, chronic conditions, psychiatric disorders, and obesity drugs (improved bioavailability).
Direct-to-brain delivery
(Future Application)
Neurological diseases or other CNS ($17B market). No need to traverse BBB, direct routeFDA approval for 1st depression nasal spray (2019). Targets: neurodegenerative, migraine, psychedelics, etc.
